Comparing Hydrocortisone and Prednisolone for Acute Exacerbation of Chronic Obstructive Pulmonary Disease (AECOPD)
Status: Recruiting
Location: See all (14) locations...
Intervention Type: Drug
Study Type: Interventional
Study Phase: Phase 4
SUMMARY
The goal of this cluster randomized controlled trial is to determine the optimal treatment for Acute Exacerbation of Chronic Obstructive Pulmonary Disease. The study compares the effects and side effects of hydrocortisone and prednisolone in patients above 40 years old diagnosed with chronic obstructive pulmonary disease with acute exacerbation. The main question is whether there is a difference in readmission for COPD excerbation or all cause mortality within thirty days. Participants will randomized to receive treatment with either hydrocortisone or prednisolone.
Eligibility
Participation Requirements
Sex: All
Minimum Age: 40
Healthy Volunteers: f
View:
• Age ≥40 years
• Chronic obstructive pulmonary disease with acute exacerbation, unspecified: ICDJ44
Locations
Other Locations
Denmark
Amager Hospital
RECRUITING
Copenhagen
Bispebjerg Hospital
RECRUITING
Copenhagen
Frederiksberg Hospital
RECRUITING
Frederiksberg
Gentofte Hospital
RECRUITING
Hellerup
Herlev Hospital
RECRUITING
Herlev
Nordsjællands Hospital
RECRUITING
Hillerød
Holbæk Sygehus
RECRUITING
Holbæk
Hvidovre Hospital
RECRUITING
Hvidovre
University Hospital of Region Zealand, Køge
RECRUITING
Køge
Næstved Sygehus
RECRUITING
Næstved
Ringsted Sygehus
RECRUITING
Ringsted
Bornholm Hospital
RECRUITING
Rønne
University Hospital of Region Zealand, Roskilde
RECRUITING
Roskilde
Slagelse Sygehus
RECRUITING
Slagelse
Contact Information
Primary
Jens-Ulrik Stæhr Jensen, MD, PHD
jens.ulrik.jensen@regionh.dk
38673057
Backup
Pradeesh Sivapalan, MD, PHD
pradeesh.sivapalan.02@regionh.dk
29880601
Time Frame
Start Date: 2026-03-10
Estimated Completion Date: 2030-11-01
Participants
Target number of participants: 2000
Treatments
Active_comparator: Treatment with Hydrocortisone.
This arm will recieve a dose of 200 mg of Hydrocortisone intravenously once daily for five days.
Active_comparator: Treatment with Methylprednisolone
This arm will recieve a dose of 40 mg of Methylprednisolone intravenously once daily for five days.
Related Therapeutic Areas
Sponsors
Leads: Copenhagen Respiratory Research